CD3+
CD3+ refers to cells that express the cluster of differentiation 3 (CD3) glycoprotein complex, a surface antigen expressed on the majority of T lymphocytes and a critical component of the T cell receptor (TCR) signaling machinery.
CD3+ refers to cells that express the cluster of differentiation 3 (CD3) glycoprotein complex, a surface antigen expressed on the majority of T lymphocytes and a critical component of the T cell receptor (TCR) signaling machinery. As an essential marker of T cell identity and function, CD3 plays a fundamental role in T cell development, thymic selection, and antigen-driven T cell activation. Beyond its developmental significance, CD3 has emerged as a major therapeutic target in immuno-oncology, particularly through the design of bispecific and multispecific antibodies that redirect T cells toward tumor cells expressing specific tumor-associated antigens. These CD3-engaging therapeutics, known as T cell engagers, include BiTEs (bispecific T cell engagers), which leverage the inherent cytotoxic capacity of T cells to generate durable anti-tumor responses.
Where the papers sit
15 papers from the last 6 months study CD3+ directly · updated from PubMed 16 Nov 2026
Study type 5 clinical trials · 4 observational · 6 preclinical
Themes 3 themes
-
Engineered CD3 T-Cell Engagers
Engineered CD3 T-cell engagers are moving beyond conventional surface targets through FAP×CD3, TCR-mimic recognition of intracellular antigens and affinity or valency tuning. Preclinical work spans solid-tumor cytotoxicity, BCMA-directed B-cell depletion and activity at distant untreated tumor sites. DNA hypomethylating agents are being used to preserve T-cell stemness and strengthen responses. Broad target coverage, controlled activation and translation from preclinical models remain the central challenges.
6 papers · 40%
-
Bispecific Therapy in Myeloma
Teclistamab and talquetamab are extending T-cell redirection in relapsed or refractory multiple myeloma, including talquetamab–daratumumab combinations. Cytokine release syndrome, infections, B-cell effects and GPRC5D-related toxicities recur as the main management problems. Dexamethasone and structured adverse-event monitoring support treatment delivery. QSP modeling and pharmacovigilance point toward better dosing and safety mitigation, while durability and comparative benefit remain open.
5 papers · 33.3%
-
T-Cell Engagers in B-Cell Malignancies
CD3 bispecifics are moving B-cell malignancy treatment toward deep, measurable remissions, with epcoritamab MRD negativity and blinatumomab-based pretransplant therapy linking T-cell redirection to relapse control. Glofitamab and related agents are being evaluated across relapsed lymphoma and transplant settings. Peripheral CD4+ T-cell reserve may help predict response, while donor-lymphocyte redirection seeks stronger graft-versus-leukemia effects. Durability, immune competence and integration with BTK inhibition or allotransplant remain unresolved.
4 papers · 26.7%
Papers
The 15 papers from the last 6 months that study CD3+ directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Engineered CD3 T-Cell Engagers (6)
- The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
- Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy. Science bulletin · 10 Sept 2026 PMID 42722595
- Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors. Proceedings of the National Academy of Sciences of the United States of America · 4 Sept 2026 PMID 42696537
- Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
- TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. Signal transduction and targeted therapy · 24 Jun 2026 PMID 42342658
- DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524
Bispecific Therapy in Myeloma (5)
- Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
- Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience. Hematology (Amsterdam, Netherlands) · 1 Sept 2026 PMID 42679119
- Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. The New England journal of medicine · 15 Jun 2026 PMID 42294841
- Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
- Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
T-Cell Engagers in B-Cell Malignancies (4)
- Peripheral CD4+ T-Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor-Associated Immune Modulation in B-Cell Lymphoma. Hematological oncology · 10 Oct 2026 PMID 42858312
- MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. Blood advances · 10 Jul 2026 PMID 42431612
- Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
- "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL. Blood advances · 20 May 2026 PMID 42160762
By study type
Clinical trials (5)
- Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience. Hematology (Amsterdam, Netherlands) · 1 Sept 2026 PMID 42679119
- MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. Blood advances · 10 Jul 2026 PMID 42431612
- Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. The New England journal of medicine · 15 Jun 2026 PMID 42294841
- Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
- Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
Observational studies and case reports (4)
- Peripheral CD4+ T-Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor-Associated Immune Modulation in B-Cell Lymphoma. Hematological oncology · 10 Oct 2026 PMID 42858312
- Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
- Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
- "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL. Blood advances · 20 May 2026 PMID 42160762
Preclinical: animal, cell and lab studies (6)
- The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
- Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy. Science bulletin · 10 Sept 2026 PMID 42722595
- Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors. Proceedings of the National Academy of Sciences of the United States of America · 4 Sept 2026 PMID 42696537
- Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
- TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. Signal transduction and targeted therapy · 24 Jun 2026 PMID 42342658
- DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-08-12. Last written: 2026-09-17 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.